In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents

Abstract

The in vitro activity of Bay 09867, a new quinoline derivative, was compared with those of norfloxacin, nalidixic acid, ceftazidime, cefaclor, cefuroxime, gentamicin, and other antimicrobial agents, when appropriate, against 410 A new cluinoline derivative, 1-cyclopropyl-6-fluro-1, 4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid hydrochloride (Bay 09867) (Fig. 1 Inocula were prepared in the following manner. For all strains except those of B. fragilis, streptococci (including pneumococci), N. gonorrhoeae, and H. influenzae, the organisms were grown overnight in nutrient broth yielding a viable count of about 109 CFU/ml. H. influenzae, B. fragilis, and streptococcal strains were grown overnight in Levintal broth, thioglycolate broth, and Todd-Hewitt broth, respectively, yielding comparable viable counts. Pneumococci were also grown in Todd-Hewitt broth, and the viable count was 108 CFU/ml. N. gonorrhoeae strains were grown overnight on a chocolate agar plate, and the growth was removed just before use and suspended in peptone water to yield a viable count of 106 and 107 CFU/ml. Two inocula of 104 and 106 CFU, respectively, were used to test all the strains except N. gonorrhoeae and the pneumococci and were obtained by transferring 1 ,ul of an appropriate dilution of the overnight culture to the surface of the antibiotic-containing agar by a multipoint inoculating device (Denley-Tech Ltd., Billingshurst, England

Peroral treatment with ciprofloxacin of patients with spinal cord lesion and bacteriuria caused by multiply resistant bacteria

“…However, the half-life is considerably shorter in our patients (Table III) than in other studies where it was found to range between 3 and 5 hours (Wingender et al, 1984;Borner et al, 1986). High concentrations of ciproftoxacin were achieved in the urine and in most of the dosing interval by far exceeding the minimal concentrations necessary to inhibit growth of urinary tract pathogens (Wise et al, 1983;Fass, 1983). In a few of our patients the concentration towards the end of the interval was rather low and taking into account the relatively short half-life a twice daily schedule should be recommended for this dosage of ciproftoxacin.…”

“…Cipro ftoxacin is a structural analogue of nalidixic acid and has very high in vitro activity against a wide variety of organisms including multiply resistant bacteria (Wise et al, 1983). The purpose of this investigation was therefore to evaluate the clinical and bacteriological efficacy of ciproftoxacin in SCL patients with urinary tract infection which were resistant to other peroral therapy.…”

Untitled

“…It is believed that the mode of action of this family of drugs is through binding DNA-gyrase enzyme 2 . It is also reported that there is a direct correlation of fluoroquinolone bonding with inhibition of DNA-gyrase enzyme activity and induction of DNA breakage.…”

Activities of pefloxacin and ciprofloxacin in experimentally induced Pseudomonas pneumonia in neutropenic guinea pigs

“…Further studies with these drugs in the therapy of Pseudomonas sp. infections are warranted.Pefloxacin and ciprofloxacin are two new quinoline carboxylic acid derivatives (12,15). Although structurally similar to nalidixic acid, the spectrum of activity of pefloxacin and ciprofloxacin includes Enterobacteriaceae, Pseudomonas sp., and many gram-positive cocci.…”